Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injectable pre-filled single dose syringe products for use in the emergency treatment of acute allergic reactions comprising anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was founded in 2006 and is headquartered in San Diego, California.
We understand, that you have no intention on buying any shares of ADMP... With that said, do you just enjoy spreading propaganda throughout Investment boards...? Your motive is clear and we feel that nows the time to take your ball and leave so the big kids can play....
And for the major investment firms and institutions that aren’t interested in ADMP, well maybe you can spend your time calling them and informing them how crazy they are for investing 100’s and thousands of shares in ADMP....